Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Total Liabilities of $748.6 million for Q4 2025, up 20.73% year-over-year from $620.1 million in Q4 2024, and up 20.73% quarter-over-quarter from $620.1 million in Q4 2024.
Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Total Liabilities for 3 consecutive years, with $748.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 20.73% year-over-year to $748.6 million; the TTM figure through Dec 2025 stood at $748.6 million (up 20.73% YoY), while the FY2025 annual figure was $748.6 million, up 27.44% from the prior year.
- Total Liabilities advanced to $748.6 million in Q4 2025 per TLX's latest filing, from $620.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $748.6 million in Q4 2025 and bottomed at $167.3 million in Q4 2023.
- Historically, Total Liabilities has averaged $512.0 million across 3 years, with a median of $620.1 million in 2024.
- Annual changes were most pronounced in 2024 — Total Liabilities soared 270.57% — and 2025, when it advanced 20.73%.
- Telix Pharmaceuticals' Total Liabilities stood at $167.3 million in 2023, then soared by 270.57% to $620.1 million in 2024, then climbed by 20.73% to $748.6 million in 2025.
- Business Quant data shows TLX's Total Liabilities at $748.6 million in Q4 2025, $620.1 million in Q4 2024, and $167.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | 748.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 748.61 Mn |
| Dec 31, 2024 | 620.09 Mn |
| Dec 31, 2023 | 167.34 Mn |